Nussberger J, Bühler K, Waeber B, Brunner H R
J Cardiovasc Pharmacol. 1986;8 Suppl 10:S23-8. doi: 10.1097/00005344-198600101-00006.
The introduction of pharmacological inhibitors of renin and angiotensin (ANG) converting enzyme in cardiovascular therapy drew new attention to the role of the renin-angiotensin system in regulating circulatory homeostasis. Accurate measurement of very low concentration of the biologically active peptides ANG II and ANG III sometimes in the presence of large amounts of inactive precursors and metabolites is needed. Active and inactive angiotensins have been measured specifically in attomolar quantities by radioimmunoassay after rapid extraction on bonded-phase silica and subsequent high-performance liquid chromatography. ANG II was found to be generated in cold plasma containing conventional inhibitors; it was concluded that renin, converting enzyme, and angiotensinases must be inhibited if physiological ANG concentrations are to be estimated. Modification of the antigen enhanced the specificity of the ANG II antisera. Monoclonal antibodies to ANG II were produced.
肾素和血管紧张素（ANG）转换酶的药理抑制剂在心血管治疗中的应用，使人们重新关注肾素-血管紧张素系统在调节循环稳态中的作用。有时需要在存在大量无活性前体和代谢物的情况下，准确测量极低浓度的生物活性肽ANG II和ANG III。通过在键合相硅胶上快速萃取并随后进行高效液相色谱法，已通过放射免疫测定法以阿托摩尔量特异性测量了活性和非活性血管紧张素。发现在含有常规抑制剂的冷血浆中会生成ANG II；得出的结论是，如果要估计生理ANG浓度，必须抑制肾素、转换酶和血管紧张素酶。抗原的修饰提高了ANG II抗血清的特异性。制备了针对ANG II的单克隆抗体。
